Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 19/20 | 0.62 |
| ▸ | HRH1 | P35367 | 5/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | HRH2 | P25021 | 4/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.58 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4670397 | 0.91 | HRH3 (0.75) | HRH3KCNH2 | |
| SCHEMBL4670412 | 0.88 | HRH3 (0.64) | HRH3KCNH2 | |
| SCHEMBL4670379 | 0.85 | HRH3 (0.63) | HRH3HRH1KCNH2 | |
| SCHEMBL4673196 | 0.81 | HRH3 (0.61) | HRH3HRH1KCNH2 | |
| SCHEMBL4670358 | 0.81 | HRH3 (0.61) | HRH3HRH1KCNH2 | |
| SCHEMBL4224193 | 0.80 | HRH3 (0.61) | HRH3HRH1CYP2D6HRH2KCNH2 | |
| SCHEMBL14565799 | 0.80 | HRH3 (0.73) | HRH3HRH1CYP2D6HRH2KCNH2 | |
| Hydrochloric Acid SCHEMBL4233278 | 0.80 | HRH3 (0.61) | HRH3HRH1CYP2D6HRH2KCNH2 | |
| SCHEMBL4229736 | 0.79 | HRH3 (0.63) | HRH3HRH1CYP2D6HRH2KCNH2 | |
| SCHEMBL4229884 | 0.79 | HRH3 (0.63) | HRH3HRH1CYP2D6HRH2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1610786-B9 | 4-(4-(HETEROCYCLYLALKOXY PHENYL)-1-(HETEROCYCLYL-CARBONYL)PIPERIDINE DERIVATIVES AND RELATED COMPOUNDS AS HISTAMINE H3 ANTAGONISTS FOR THE TREATMENT OF NEUROLOGICAL DISEASES SUCH AS ALZHEIMER'S | GLAXO GROUP LTD (GB) | 2008-02-27 | — | — | EP | claimed |
| EP-1610786-B1 | 4-(4-(HETEROCYCLYLALKOXY PHENYL)-1-(HETEROCYCLYL-CARBONYL)PIPERIDINE DERIVATIVES AND RELATED COMPOUNDS AS HISTAMINE H3 ANTAGONISTS FOR THE TREATMENT OF NEUROLOGICAL DISEASES SUCH AS ALZHEIMER'S | GLAXO GROUP LTD (GB) | 2007-06-20 | — | — | EP | claimed |
| US-20060205774-A1 | 4-(4-(Heterocyclylakoxy) phenyl-1-(heterocyclyl-carbonyl) piperidine derivavites and related compounds as histamine h3 antagonists for the treatment of neurological diseases such as alzheimer's | GLAXO GROUP LIMITED (GB) | 2006-09-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205774-A1 | 4-(4-(Heterocyclylakoxy) phenyl-1-(heterocyclyl-carbonyl) piperidine derivavites and related compounds as histamine h3 antagonists for the treatment of neurological diseases such as alzheimer's | HRH3, HRH4, HRH1 | HRH3 1/4885HRH1 3/4885CYP2D6 1992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.